FdaApplication
NDA 021038
Identifiers
- fda_app_no: NDA021038
Properties
| Property | Value |
|---|---|
| applicant_name | HOSPIRA INC |
| application_type | NDA |
| approval_date | 1999-12-17 |
Revenue by product
PRECEDEX
| Period | Revenue |
|---|---|
| Q3 2021 | $50.0M |
| Q2 2021 | $42.0M |
| Q1 2021 | $55.0M |
| Q3 2020 | $55.0M |
| Q2 2020 | $114.0M |
| Q1 2020 | $42.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients.
Products (5)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| PRECEDEX | DEXMEDETOMIDINE HYDROCHLORIDE | EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML) | INJECTABLE;INJECTION |
| PRECEDEX | DEXMEDETOMIDINE HYDROCHLORIDE | EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) | INJECTABLE;INJECTION |
| PRECEDEX | DEXMEDETOMIDINE HYDROCHLORIDE | EQ 80MCG BASE/20ML (EQ 4MCG BASE/ML) | INJECTABLE;INJECTION |
| PRECEDEX | DEXMEDETOMIDINE HYDROCHLORIDE | EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML) | INJECTABLE;INJECTION |
| PRECEDEX | DEXMEDETOMIDINE HYDROCHLORIDE | EQ 1MG BASE/250ML (EQ 4MCG BASE/ML) | INJECTABLE;INJECTION |
5 products